Molecular Pathology Sample Suitability Patents: Who Holds the Claims
A cluster of academic and cancer-center filers, not industrial diagnostics firms, holds the leading positions — the top-ranked assignee sits at 8 records against a field of 31 ranked companies. Filings peaked at 8 in 2019. The tracked span from 2021 (3 records) to 2024 (1 record) shows a 67% drop — the last year in the dataset that can be treated as complete. Years after 2024 are still being backfilled by publication lag and should not be read as a continued decline.
- 1UNIVERSITAETSKLINIKUM HAMBURG EPPENDORF8
- 2TRANSLATIONAL GENOMICS RESEARCH INSTITUTE7
- 3CGFL CENT GEORGES FRANCOIS LECLERC7
- 4UNIV DE BOURGOGNE (FR)7
- 5OSI PHARMACEUTICALS INC7
See the full molecular pathology sample suitability analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents on molecular pathology sample suitability?
The leading assignee in this dataset holds 8 records out of 31 ranked companies, with fifth place at 7 and tenth place at 5 — a gradual taper rather than one dominant holder. The ranked leaders are drawn mostly from cancer research centers and affiliated universities rather than commercial diagnostics manufacturers. Because the ranking counts patent families rather than raw document counts, it reflects distinct inventions rather than continuation filings or multi-jurisdiction duplicates.
Is patent filing in this space growing or slowing down?
Filing peaked at 8 records in 2019 and the tracked 2021-to-2024 span shows a 67% decline, which is the most recent period that can be treated as complete. Filings from 2025 onward are still understated because publication typically lags the original filing date by about 18 months. Readers should treat the apparent recent drop as a data artifact in the newest years rather than confirmed evidence that the field is contracting.
What patent classes cover tumor cell content and DNA yield testing?
C12Q, covering measuring and testing involving enzymes and nucleic acids, appears on 84.7% of the 59 records in scope, making it by far the dominant class. G16B bioinformatics (30.5%) and G01N material analysis (22.0%) form a secondary layer, often combined with C12Q on the same record. Because a single record can carry several IPC codes, these percentages sum to more than 100% and should not be read as mutually exclusive categories.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Molecular Pathology Sample Suitability covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.